ArriVent BioPharma annual ebitda
2022
2023
2024
2025
ArriVent BioPharma EBITDA Growth & History (AVBP)
ArriVent BioPharma's calculated EBITDA was −$177.5M for fiscal 2025.
View full ArriVent BioPharma company overviewArriVent BioPharma annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$177.5M | −$83.2M | — |
| 2024 | 2024-12-31 | −$94.3M | −$19.7M | — |
| 2023 | 2023-12-31 | −$74.6M | −$37.7M | — |
| 2022 | 2022-12-31 | −$36.9M | — | — |
ArriVent BioPharma quarterly ebitda
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$52.7M | −$19.1M | — |
| Q1 2026 | 2026-03-31 | −$46.1M | $20.7M | — |
| Q4 2025 | 2025-12-31 | −$38.8M | — | — |
| Q3 2025 | 2025-09-30 | −$38.3M | — | — |
| Q2 2025 | 2025-06-30 | −$33.6M | — | — |
| Q1 2025 | 2025-03-31 | −$66.8M | — | — |
ArriVent BioPharma ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, ArriVent BioPharma's ebitda decreased from −$36.9M to −$177.5M, a change of −$140.6M. The latest reported quarter, Q2 2026, shows −$52.7M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review ArriVent BioPharma source filings ↗